Evidence map›Paper›PMID 33836674›Full record

ArticleBMC cancer2021

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.

Gokce Askan, Ibrahim Halil Sahin, Joanne F Chou, Aslihan Yavas, Marinela Capanu, Christine A Iacobuzio-Donahue, Olca Basturk, Eileen M O'Reilly

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Cancer Stem Cells in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gokce Askan *Memorial Sloan Kettering Cancer Center, 300 East 66th street, office 1021, New York, NY, 10065, USA.
Ibrahim Halil Sahin *H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
Joanne F ChouMemorial Sloan Kettering Cancer Center, 300 East 66th street, office 1021, New York, NY, 10065, USA.
Aslihan YavasMemorial Sloan Kettering Cancer Center, 300 East 66th street, office 1021, New York, NY, 10065, USA.
Marinela CapanuMemorial Sloan Kettering Cancer Center, 300 East 66th street, office 1021, New York, NY, 10065, USA.
Christine A Iacobuzio-DonahueMemorial Sloan Kettering Cancer Center, 300 East 66th street, office 1021, New York, NY, 10065, USA.
Olca BasturkMemorial Sloan Kettering Cancer Center, 300 East 66th street, office 1021, New York, NY, 10065, USA.
Eileen M O'ReillyMemorial Sloan Kettering Cancer Center, 300 East 66th street, office 1021, New York, NY, 10065, USA. oreillye@mskcc.org.ORCID http://orcid.org/0000-0002-8076-9199
Memorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008478NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundHerein, we investigate the relationship between pancreatic stem cell markers (PCSC markers), CD44, and epithelial-specific antigen (ESA), tumor stroma, and the impact on recurrence outcomes in pancreatic ductal adenocarcinoma (PDAC) patients.

methodsPDAC patients who underwent surgical resection between 01/2012-06/2014 were identified. CD44 and ESA expression was assessed by immunohistochemistry. Stroma was classified as loose, moderate, and dense based on fibroblast content. Overall survival (OS) and relapse-free survival (RFS) were estimated using the Kaplan-Meier method and compared between subgroups by log-rank test. The association between PCSC markers and stroma type was assessed by Fisher's exact test.

resultsN = 93 PDAC patients were identified. The number of PDAC patients with dense, moderate density, and loose stroma was 11 (12%), 51 (54%), and 31 (33%) respectively. PDAC with CD44

conclusionsThese data indicate PCSCs may have an important role in stroma differentiation in PDAC. Our results further suggest that tumor stroma may influence the recurrence pattern in PDAC patients.

Indexed as

BiomarkersCancer-Associated FibroblastsCarcinoma, Pancreatic DuctalCombined Modality TherapyFemaleHumansImmunohistochemistryMaleNeoplasm GradingNeoplasm MetastasisNeoplasm StagingNeoplastic Stem CellsPancreatic NeoplasmsPrognosisRecurrenceStromal CellsBiomarkersCancer stem cellsCD44DesmoplasiaESAPancreatic cancerPancreatic ductal adenocarcinomaRecurrence patternSonic hedgehogTumor microenvironmentTumor stroma

Identifiers

PMID33836674
PMCPMC8034174
OpenAlexW3128309191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.